Codeine versus placebo for chronic cough in children.

Area of Science:

• Pediatric Pulmonology
• Clinical Pharmacology
• Evidence-Based Medicine

Background:

• Chronic cough in children is common, leading to significant healthcare use and parental burden.
• Persistent cough may signal serious conditions like foreign body aspiration or bronchiectasis.
• Codeine, an antitussive, carries risks including respiratory depression and addiction, particularly in children due to metabolic variability.

Purpose of the Study:

• To systematically review the safety and efficacy of codeine and its derivatives for treating chronic cough in pediatric populations.
• To evaluate the quality of existing evidence for codeine use in children with persistent cough.

Main Methods:

• Searched multiple databases (Cochrane, MEDLINE, EMBASE, ClinicalTrials.gov) for randomized controlled trials (RCTs) up to June 2016.
• Included studies involving children (<18 years) with chronic cough (≥4 weeks) comparing codeine/derivatives to placebo.
• Two independent reviewers screened studies for eligibility.

Main Results:

• No RCTs met the inclusion criteria, yielding no evidence to support or refute codeine's use for chronic cough in children.
• Existing reviews on acute cough also show a lack of evidence for codeine efficacy.
• Regulatory bodies and experts advise against codeine for children under 12 and those 12-18 with respiratory issues due to risks and lack of proven benefit.

Conclusions:

• Absence of RCTs means no data supports codeine for childhood chronic cough.
• Potential adverse events (respiratory suppression, opioid toxicity) lead regulatory authorities to recommend against codeine use in children under 12.
• Clinical practice should follow guidelines, avoiding codeine for pediatric cough and focusing on etiological management.